55 Participants Needed

Decitabine + Cedazuridine + Venetoclax for Acute Myeloid Leukemia

Recruiting at 7 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 1 & 2
Sponsor: National Cancer Institute (NCI)
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial protocol does not specify if you must stop taking your current medications. However, you cannot take certain medications that interact with the trial drugs, and you should discuss any current medications with the trial team to ensure they are permitted.

What data supports the effectiveness of the drug combination of Decitabine, Cedazuridine, and Venetoclax for treating Acute Myeloid Leukemia?

Research shows that combining Venetoclax with Decitabine improves survival and response rates in older adults with acute myeloid leukemia compared to Decitabine alone. In one study, patients receiving this combination had a longer median overall survival and higher response rates, indicating its effectiveness in treating this condition.12345

Is the combination of Decitabine, Cedazuridine, and Venetoclax safe for humans?

The combination of Venetoclax with Decitabine has been studied in older patients with acute myeloid leukemia and was generally well tolerated, with common side effects including nausea, diarrhea, and fatigue. No severe complications like tumor lysis syndrome (a condition where cancer cells break down rapidly) were observed in the studies.14567

How is the drug combination of Decitabine, Cedazuridine, and Venetoclax unique for treating acute myeloid leukemia?

This drug combination is unique because it combines Decitabine and Cedazuridine with Venetoclax, which has shown improved activity in high-risk acute myeloid leukemia patients, especially those who are older or unfit for intensive chemotherapy. The combination has demonstrated longer survival and higher response rates compared to Decitabine alone.24678

What is the purpose of this trial?

This phase Ib/II trial studies the effects of ASTX727 (decitabine and cedazuridine) in combination with venetoclax in treating patients with higher-risk acute myeloid leukemia patients who do not have a change in the gene called fms-like tyrosine kinase 3 (FLT3). Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Cedazuridine is an enzyme inhibitor. It helps to increase the amount of decitabine in the body so that the medication will have a greater effect. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. Venetoclax may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Venetoclax and decitabine are commonly given together for older patients with AML ASTX727 (a pill form of decitabine + cedazuridine) has been found to be equal to decitabine (given intravenously), and this part of the study is to confirm that venetoclax and ASTX727 is as safe as venetoclax and decitabine given intravenously. This study allows for lowering doses of study drugs to assure the dose chosen for the randomized study (second portion of this trial) is safe and tolerable for people. Giving ASTX727 in combination with venetoclax may help in the treatment of patients with higher-risk acute myeloid leukemia.

Research Team

Michael R Savona

Michael Savona, MD

Principal Investigator

Yale University Cancer Center LAO

Eligibility Criteria

This trial is for adults aged 18-65 with higher-risk acute myeloid leukemia (AML) who haven't had certain previous treatments. Participants must have an ECOG performance status of <=2, no FLT3 gene mutations, and adequate organ function. They should not be pregnant or breastfeeding and must agree to use contraception.

Inclusion Criteria

I have recovered from side effects of previous treatments, except for hair loss.
My tumor-related complications were treated before starting therapy.
My heart pumps blood well, with an ejection fraction of 50% or higher.
See 14 more

Exclusion Criteria

Inability to tolerate oral medication or keep a pill diary
I do not have any ongoing infections that are not being successfully treated.
I have active leukemia in my brain or spinal cord.
See 12 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Phase Ib Treatment

Patients receive ASTX727 orally and venetoclax daily, with treatment repeating every 28 days for up to 12 cycles.

Up to 48 weeks
Monthly visits for treatment and monitoring

Phase II Treatment

Patients are randomized to receive either ASTX727 and venetoclax or cytarabine and daunorubicin, with treatment repeating every 28 days.

Up to 24 weeks
Monthly visits for treatment and monitoring

Follow-up

Participants are monitored for safety and effectiveness after treatment completion.

Up to 5 years
Every 3 months

Treatment Details

Interventions

  • Decitabine and Cedazuridine
  • Venetoclax
Trial Overview The study tests ASTX727 (oral decitabine + cedazuridine) combined with venetoclax in AML patients without the FLT3 mutation. It aims to confirm if this combination is as safe as intravenous decitabine with venetoclax, potentially improving treatment for high-risk AML.
Participant Groups
3Treatment groups
Experimental Treatment
Active Control
Group I: Phase Ib (decitabine and cedazuridine, venetoclax)Experimental Treatment4 Interventions
Patients receive ASTX727 PO QD on days 1-4 or 1-5 of each cycle and venetoclax PO QD on days 1-28 or days 1-21 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy and collection of blood samples throughout the trial.
Group II: Arm I (decitabine and cedazuridine, venetoclax)Experimental Treatment4 Interventions
Patients receive ASTX727 PO QD at the recommended phase II dose and venetoclax PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy and collection of blood samples throughout the trial.
Group III: Arm II (cytarabine, daunorubicin)Active Control3 Interventions
Patients receive cytarabine IV over 24 hours on days 1-7 of each cycle and daunorubicin IV over 10-30 minutes on days 1-3 of each cycle. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy throughout the trial.

Decitabine and Cedazuridine is already approved in European Union, United States for the following indications:

🇪🇺
Approved in European Union as Inaqovi for:
  • Acute myeloid leukemia (AML) in adults who are ineligible for standard induction chemotherapy
🇺🇸
Approved in United States as ASTX727 for:
  • Adult patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities precluding intensive induction chemotherapy

Find a Clinic Near You

Who Is Running the Clinical Trial?

National Cancer Institute (NCI)

Lead Sponsor

Trials
14,080
Recruited
41,180,000+

Findings from Research

In a study of 22 heavily pre-treated patients with relapsed or refractory acute myeloid leukaemia (RR-AML), the combination of venetoclax and decitabine resulted in a 45.5% overall response rate, with 40.9% achieving complete remission, demonstrating its efficacy in a real-world setting.
While the treatment was effective, it was associated with significant side effects, including grade IV neutropenia and thrombocytopenia in all patients, but no deaths were attributed to the treatment side effects, indicating that the adverse effects were manageable.
Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World Setting.Tong, J., Zhao, N., Hu, X., et al.[2022]
In a study comparing older adults with newly diagnosed acute myeloid leukemia (AML), those treated with the combination of decitabine (DEC) and venetoclax (VEN) had a significantly longer median overall survival of 13.4 months compared to 8.3 months for those receiving DEC alone.
The combination therapy also resulted in a higher response rate of 70.3% versus 24.3% for DEC monotherapy, indicating that DEC+VEN is more effective in treating AML without increasing short-term mortality rates.
Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis.Kwag, D., Cho, BS., Bang, SY., et al.[2022]
A 50-year-old male with relapsed acute myeloid leukemia (AML) achieved complete remission after being treated with decitabine and venetoclax as a fifth-line therapy, demonstrating the potential efficacy of this combination in difficult-to-treat cases.
Following remission, the patient successfully underwent a haploidentical transplant, resulting in an overall survival of 48.6 months, suggesting that this treatment approach may serve as a viable bridge to transplant for patients with multiresistant AML.
Efficacy of Decitabine and Venetoclax as Salvage and Bridge Therapy to Haploidentical Hematopoietic Stem Cell Transplantation in a Multiresistant Acute Myeloid Leukemia Patient.Serio, B., Giudice, V., Morini, D., et al.[2022]

References

Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World Setting. [2022]
Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis. [2022]
Efficacy of Decitabine and Venetoclax as Salvage and Bridge Therapy to Haploidentical Hematopoietic Stem Cell Transplantation in a Multiresistant Acute Myeloid Leukemia Patient. [2022]
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. [2021]
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. [2021]
Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings. [2021]
A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia. [2022]
SARS-CoV-2 Infection in Patients Treated with Azacitidine and Venetoclax for Acute Leukemia: A Report of a Case Series Treated in a Single Institution. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security